For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Ariad Pharmaceuticals, Inc.

USPTO Granted Patents = 69

% Expired Patents = 21.7

CIPO Patents = 13

EPO Patents = 14

Trademarks = 5

Forward Citations = 621

Loading Chart...

Loading Chart...

76 inventors (with patents filed for the assignee):

William C Shakespeare (34 out of 36 patents)

Yihan Wang (33 out of 36 patents)

David C Dalgarno (24 out of 25 patents)

4. Tomi K Sawyer (22 out of 35 patents)

5. Xiaotian Zhu (22 out of 39 patents)

6. Wei-Sheng Huang (21 out of 22 patents)

7. Chester A Metcalf, Iii (20 out of 34 patents)

8. Rajeswari Sundaramoorthi (19 out of 19 patents)

9. Leonard W Rozamus (15 out of 23 patents)

10. Jiwei Qi (14 out of 14 patents)

11. R Mathew Thomas (13 out of 14 patents)

12. Feng Li (11 out of 14 patents)

13. Regine Bohacek (11 out of 12 patents)

14. Dong Zou (10 out of 15 patents)

15. Pradeep Kumar Sharma (10 out of 15 patents)

Core Competencies:

Kinase Inhibitors

c-Kit

HPK1

Cancer Treatment

Crystalline Forms

Acetylenic Compounds

Signal Transduction

Immunosuppressants

Phosphorus Derivatives

Aminothiazole

Anilinopyrimidines

Heteroaryl

69 patents: Sort by Forward Citations

1. 11753404 - Aminothiazole compounds as c-Kit inhibitors (2023-09-12),

2. 11384086 - Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2022-07-12),

3. 11279705 - Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2022-03-22),

4. 11192897 - Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2021-12-07),

5. 11192896 - Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2021-12-07),

6. 11192895 - Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2021-12-07),

7. 11180482 - Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors (2021-11-23),

8. 11117883 - Benzimidazole compounds as c-Kit inhibitors (2021-09-14),

9. 11001580 - Aminothiazole compounds as c-Kit inhibitors (2021-05-11),

10. 10934317 - Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine (2021-03-02),

11. 10662197 - Crystalline forms of 3-(imidazo[1,2-b)pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2020-05-26),

12. 10385078 - Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine (2019-08-20),

13. 10227342 - Heteroaryl compounds for kinase inhibition (2019-03-12),

14. 10125136 - Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2018-11-13),

15. 9834571 - Compounds for inhibiting cell proliferation in EGFR-driven cancers (2017-12-05),

Company Overview

Ariad Pharmaceuticals, Inc., based in Cambridge, MA, specializes in the development of innovative therapies targeting cancer through kinase inhibitors. The company focuses on advancing treatments that inhibit specific kinases, such as c-Kit and HPK1, which play critical roles in cancer progression and signal transduction. Ariad's research encompasses various core technology topics, including crystalline forms and acetylenic compounds, aimed at improving patient outcomes in oncology and immunosuppressive therapies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

69 Patents

#41 in Cambridge, MA

#296 in Massachusetts

#5,311 in US

#10,763 in the World

Cambridge, MA, United States of America

Ariad Pharmaceuticals, Inc.

Forward Citations = 621

76 inventors:

William C Shakespeare (34 out of 36 patents)

Yihan Wang (33 out of 36 patents)

David C Dalgarno (24 out of 25 patents)

4. Tomi K Sawyer (22 out of 35 patents)

5. Xiaotian Zhu (22 out of 39 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ariad Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/ariad-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…